Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul

In This Article:

Key Points

  • The markets are down this year amid concerns about the economy and tariffs.

  • Many solid stocks are struggling and could make for excellent buys right now.

  • The stocks listed here are trading at attractive earnings multiples and have promising futures ahead.

Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. And that's after recovering recently -- it was down much more than that in early April when global tariffs were first announced. But make no mistake, the risk isn't gone, and while a full-blown crash has taken a pause lately, that doesn't mean more of a sell-off isn't coming.

The good news, however, is that if you're a long-term investor, a crash in the markets can open up some great buying opportunities. Three stocks that are down over 10% this year and trading at low earnings multiples are Pfizer (NYSE: PFE), PayPal (NASDAQ: PYPL), and Builders FirstSource (NYSE: BLDR). Here's why they may be worth loading up on right now.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Pfizer

Investors haven't been all that bullish on Pfizer this year -- it's down 13% thus far in 2025. But it's hard to blame the market for the lack of excitement as the business is struggling to grow these days, as Pfizer expects its top line this year to be nearly unchanged from the previous year, and at worst, it could decline.

For long-term investors, this presents a great chance to load up on the healthcare stock. It trades at a forward price-to-earnings (P/E) multiple of less than 8 (based on analyst expectations), and the company has been gearing up for more growth ahead. CEO Albert Bourla has acknowledged that the company will face adversity because of generics, which could result in it losing as much as $18 billion in revenue from its top line by the end of the decade. But at the same time, through in-house development and acquisitions, it plans to add $25 billion.

It has acquired multiple businesses in recent years, including oncology company Seagen, in an effort to bolster its long-term prospects. Management expects Seagen could contribute up to $10 billion in revenue by the end of the decade (up from over $3 billion last year). Pfizer is also optimistic about its mRNA pipeline, projecting that business to bring in between $10 billion and $15 billion by 2030.

Last year, it also obtained approval for a gene therapy treatment, Beqvez, to treat adults with moderate to severe hemophilia B (a rare bleeding disorder). The gene therapy market is in its early stages but it has the potential to be a huge opportunity for pharma giants like Pfizer. Overall, the company has a wealth of assets in its pipeline with currently more than 100 drug candidates in clinical trials.